Abstract: In an example embodiment, an analog to digital converter (ADC) facilitating passive analog sample and hold is provided and includes a pair of binary weighted conversion capacitor arrays, a pair of sampling capacitors, and a plurality of switches that configure each conversion capacitor array and the sampling capacitors for a sampling phase, a charge transfer phase, and a bit trial phase. During the sampling phase, the sampling capacitors are decoupled from the conversion capacitors and coupled to an analog input voltage. During the charge transfer phase, the sampling capacitors are coupled to the conversion capacitors and decoupled from the analog input voltage. During the bit trial phase, the sampling capacitors are decoupled from the conversion capacitors.

Abstract: Ethernet fault management systems and methods using programmable Type-Length-Value (TLV) offsets combine software-based Operations, Administration, and Maintenance (OAM) protocol support with hardware-based fault management support to delegate generation and processing of OAM protocol messages to hardware devices with the software-based protocol support used to program hardware based on fixed offsets in the OAM protocol messages. The hardware can be designed to be flexible since the hardware can be agnostic to the logic within the OAM protocol which would reside in the software. The Ethernet fault management systems and methods combine the flexibility of software-based approaches with the speed and efficiency of hardware-based approaches.

Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing blood clotting disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of strokes in those with atrial fibrillation due to causes other than heart valve disease, and at least one additional risk factor for stroke (congestive heart failure, hypertension, age, diabetes, and prior stroke), and to prevent the formation of blood clots in the veins in adults operated to replace a hip or knee.

Abstract: This invention provides a method for shortstopping free radical polymerization reactions using a shortstopping agent comprising at least two alkyl hydroxylamines (AHAs) selected from the group consisting of primary AHAs, a mixture of at least one of each of primary and secondary AHAs, and salts thereof. A method for producing elastomers using the aforesaid shortstopping agents is also provided.

Abstract: A secure architecture can provide a bridge between the utility and entertainment value of online properties. An architecture that employs an internal entity that controls import and export of data (“import/export controller”) and an external entity that operates as a liaison (“data liaison”) between the import/export controller and one or more other online properties allows this bridge in a secure manner. The import/export controller and the data liaison handle data transmissions (e.g., data feeds, data updates, etc.) between the online properties without exposing resources of the online properties. The import/export controller applies rules that regulate import and export of data, and the data liaison allows the import/export controller to operate in obscurity.

Abstract: A machine, system and method for user-guided teaching of deictic references and referent objects of deictic references to a conversational system. The machine includes a system bus for communicating data and control signals received from the conversational system to the computer system, a data and control bus for connecting devices and sensors in the machine, a bridge module for connecting the data and control bus to the system bus, respective machine subsystems coupled to the data and control bus, the respective machine subsystems having a respective user interface for receiving a deictic reference from a user, a memory coupled to the system bus for storing deictic references and objects of the deictic references learned by the conversational system and a central processing unit coupled to the system bus for executing the deictic references with respect to the objects of the deictic references learned.

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of epilepsy and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of convulsions, Lennox-Gastaut syndrome, migraine, bipolar disorder, post traumatic stress disorder.

Abstract: Examples of the present disclosure describe systems and methods for authentication by an authentication component when a client attempts to access a secured resource(s). As an example, an access request is received from a client at an authentication component. The authentication component generates an authentication challenge including criteria to assist the client in selecting an appropriate authentication credential, a request for proof of possession of the authentication credential, and challenge-specific data for the client to return in a challenge response. A challenge response is received from the client. The authentication component evaluates the challenge response and determines whether to authenticate the client for access to a resource based on the evaluated challenge response. Other examples are also described.

Abstract: The invention relates to the compounds of formula I and formula Ia or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of formula I or formula Ia; and methods for treating or preventing epilepsy, seizures and convulsions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, seizures and convulsions.

Abstract: The invention relates to the compounds of formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and other inflammatory diseases.

Abstract: Techniques are described for generating configuration level signatures. In an embodiment, one or more computing devices are used to generate a first signature for a particular software deployment that is configured at a particular configuration level. The first signature is generated based on digest information that identifies a plurality of deployed source components for the particular software deployment. Mapping data is stored that maps the first signature to the digest information identifying the plurality of deployed source components for the particular software deployment. A second signature is generated based on information that defines target source components for a set of software deployments that includes the particular software deployment. The first signature is compared with the second signature to determine whether the deployed source components satisfy the target source components. An indication of whether the deployed source components satisfy the target source components is stored.

Abstract: In accordance with an embodiment, described herein is a system and method rule-based elasticity support in an application server environment. The method can begin with providing, at one or more computers, including an application server environment executing thereon, a plurality of deployable resources which can be used within the application server environment, one or more partitions, an administration server, the administration server comprising a diagnostic framework, a rules framework, and an elastic service manager, and a dynamic cluster for use by the one or more partitions. The method can continue with monitoring, by the diagnostic framework, metrics associated with the one or more partition and the dynamic cluster. The method can then trigger, by the rules framework, the action based upon a comparison between one of the one or more rules and the monitored metrics associated with the one or more partitions and the dynamic cluster.

Abstract: A circuit and method for implementing a adaptive bit-leveling function in an integrated circuit interface is disclosed. During a calibration operation, a pre-loaded data bit pattern is continuously sent from a sending device and is continuously read from an external bus by a receiving device. A programmable delay line both advances and delays each individual data bit relative to a sampling point in time, and delay counts relative to a reference point in time are recorded for different sampled data bit values, enabling a delay to be determined that best samples a data bit at its midpoint. During the advancing and delaying of a data bit, jitter on the data bit signal may cause an ambiguity in the determination of the midpoint, and solutions are disclosed for detecting jitter and for resolving a midpoint for sampling a data bit even in the presence of the jitter.

Abstract: In an embodiment, a method comprises establishing a first data communications session with a first router. In response to receiving a first request to establish a second data communications session, a probe message that is configured to test whether the first data communications session or the first router is responsive is sent to the first router. In response to determining that the first router has not acknowledged the probe message before a probe timer has expired, and receiving a second request to establish the second data communications session, the second data communications session with the first router is established and a state for the first data communications session is deleted.

Abstract: An embodiment of a radio-frequency (RF) device includes at least one transistor, a package, and a surface-mountable capacitor. The package contains the at least one transistor and includes at least one termination. The surface-mountable capacitor is coupled in a shunt configuration between the at least one transistor and a power supply terminal of the device to decouple the at least one transistor from a power supply.

Abstract: The invention relates to ketolide compounds of Formula (1) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs and stereoisomers having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing microbial infections with the compounds of invention, wherein, T is —C*H(R1)—P-Q; R, is hydrogen; unsubstituted or substituted lower alkyl, cycloalkyl or aryl; P is heteroaryl ring; Q is unsubstituted or substituted aryl or heteroaryl ring; and P is attached to Q via carbon-carbon link; and R3 is hydrogen or fluorine, With the provision that when R, is hydrogen, R3 is fluorine.

Abstract: A service is provided that supports a plurality of tenants. Server(s) of the service are communicatively coupled with a plurality of gateways of the service. Each gateway is configured to support at least one tenant. The server(s) of the service include a network interface, a tenant mapper, and a gateway interface. The network interface is configured to receive connection strings from client devices. Each received connection string includes a service portion that maps to the same public IP address of the service, and also includes a corresponding tenant portion that identifies a tenant. The tenant mapper maps the tenant portions of the connection strings to corresponding gateways. The gateway interface is configured to enable the gateways to establish tunnels between the corresponding client devices and identified tenants. Accordingly, clients are enabled to access multiple tenants of the service via a same public IP address.

Abstract: The present invention relates to additive composition and method of use thereof for controlling and inhibition of polymerization and dimerization of aliphatic monomers including butadiene comprising A) one or more of first component selected from a group comprising a) quinone methide (QM), b) quinone methide (QM) derivative including ester derivative of quinone methide, c) nitroxide (i.e. nitroxyl) compounds, and d) mixture thereof; characterized in that the composition further comprises B) one or more of second component selected from amines or polyamines, wherein the amine and polyamine is selected from a group comprising i) oxide treated tertiary amines, ii) hydroxyl alkyl tertiary amines, iii) polyether amines, and iv) mixture thereof.

Abstract: A lateral flow assay is capable of detecting and differentiating viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In some preferred embodiments, bimodal methods and devices determine if an infection is bacterial and/or viral. A dual use two strip sample analysis device includes a first lateral flow chromatographic test strip to detect MxA and a low level of C-reactive protein and a second lateral flow chromatographic test strip to detect high levels of C-reactive protein. In some preferred embodiments, the sample is a fingerstick blood sample.

Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.